Myocarditis in Adolescents (12-17 years) Associated with the Pfizer-BioNTech (BNT162b2) Vaccine: A Systematic Review and Meta-analysis
DOI:
https://doi.org/10.47672/ajhmn.1387Keywords:
Myocarditis, BNT162b2, adolescentAbstract
Purpose: Data on the incidence rate of myocarditis associated with mRNA COVID-19 vaccines in adolescents is limited. The research estimated the incidence of myocarditis associated with the Pfizer- BioNTech COVID-19 vaccine (BNT162b2) in adolescents (12-17 years).
Methodology: This study was conducted as per the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Incidence rates were estimated after generating a random effects model.
Findings: The Incidence rate in males after the first dose was 2.4 per 100,000 persons (0.8- 6.8 per 100,000; I2: 17.17%). The IR in females after the first dose was 1.9 per 100,000 persons (0.5-6.5 per 100,000; I2: 0.00). After the second dose, the IR in males was 15.7 per 100,000 persons (3.2-78.1 per 100,000; I2: 96.45%), while in females the IR after the second dose was 6.1 per 100,000 persons (2.9-12.1 per 100,000; I2: 0.00). The Incidence Rate Ratio (IRR) after the first dose between males and females was 1.86 (0.40-8.5; I2: 0.00) and 6.35 (2.98-13.49; I2: 0.00) after the second dose. Among individuals between 12- 17 years of age, myocarditis is a rare side effect associated with Pfizer- BioNTech COVID-19 vaccine (BNT162b2) vaccination. The incidence in males were about two times greater than females following the first dose and six times greater following the second dose.
Recommendation: Vaccination strategy in adolescent males needs to be revisited to mitigate risk of myocarditis.
Downloads
References
Us_Fda. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine | FDA. 2022;
Us_Fda. Spikevax and Moderna COVID-19 Vaccine | FDA. 2022;
Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naive US Military Personnel. JAMA. 2003; 289(24):3283-3289. doi:10.1001/jama.289.24.3283
Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events after COVID-19 mRNA Vaccination. JAMA - Journal of the American Medical Association. 2021;326 (14):1390-1399. doi:10.1001/jama.2021.15072
Kim RJ, Kim HW, Jenista ER, et al. Patients with acute myocarditis following mrna covid-19 vaccination. JAMA Cardiology. 2021;6(10):1196-1201. doi:10.1001/jamacardio.2021.2828
Block JP, Boehmer TK, Forrest CB, et al. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022. MMWR Morb Mortal Wkly Rep. Apr 8 2022;71(14):517-523. doi:10.15585/mmwr.mm7114e1
Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. Bmj. Dec 16 2021;375:e068665. doi:10.1136/bmj-2021-068665
Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. Jun 1 2022;7(6):600-612. doi:10.1001/jamacardio.2022.0583
Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. Jama. Jan 25 2022;327(4):331-340. doi:10.1001/jama.2021.24110
Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. Feb 2022;28(2):410-422. doi:10.1038/s41591-021-01630-0
Wong H-L, Hu M, Zhou CK, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. The Lancet. 2022;399(10342):2191-2199. doi:10.1016/S0140-6736(22)00791-7
Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. New England Journal of Medicine. 2021;385(12):1078-1090. doi:10.1056/NEJMoa2110475
Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med. Dec 2 2021;385(23):2132-2139. doi:10.1056/NEJMoa2110737
Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. Dec 2 2021; 385 (23):2140-2149. doi:10.1056/NEJMoa2109730
Brooke BS, Schwartz TA, Pawlik TM. MOOSE Reporting Guidelines for Meta-analyses of Observational Studies. JAMA Surgery. 2021; 156 (8):787-788. doi:10.1001/jamasurg.2021.0522
Wells GA, Wells G, Shea B, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014:
Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. Journal of Statistical Software. 08/05 2010; 36 (3):1 - 48. doi:10.18637/jss.v036.i03
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327 (7414):557-560. doi:10.1136/bmj.327.7414.557
Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 Vaccination in Israeli Adolescents. New England Journal of Medicine. 2022; 386 (10):998-999. doi:10.1056/NEJMc2116999
Buchan SA, Seo CY, Johnson C, et al. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. JAMA Netw Open. Jun 1 2022;5(6):e2218505. doi:10.1001/jamanetworkopen.2022.18505
Wong HL, Hu M, Zhou CK, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. Jun 11 2022;399(10342):2191-2199. doi:10.1016/s0140-6736(22)00791-7
Li X, Lai FTT, Chua GT, et al. Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong. JAMA Pediatrics. 2022;176(6):612-614. doi:10.1001/jamapediatrics.2022.0101
Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. Jama. Oct 12 2021;326(14):1390-1399. doi:10.1001/jama.2021.15072
Jain SS, Steele JM, Fonseca B, et al. COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics. Nov 2021;148(5)doi:10.1542/peds.2021-053427
Chua GT, Kwan MYW, Chui CSL, et al. Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. Nov 28 2021;doi:10.1093/cid/ciab989
June Choe Y, Yi S, Hwang I, et al. Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents. Vaccine. Jan 31 2022;40(5):691-694. doi:10.1016/j.vaccine.2021.12.044
Foltran D, Delmas C, Flumian C, et al. Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines. Eur Heart J Qual Care Clin Outcomes. Mar 2 2022;8(2):99-103. doi:10.1093/ehjqcco/qcab090
Sharff KA, Dancoes DM, Longueil JL, Johnson ES, Lewis PF. Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods. Pharmacoepidemiol Drug Saf. Aug 2022;31(8):921-925. doi:10.1002/pds.5439
Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA Vaccines. Circulation. 2021:471-484. doi:10.1161/CIRCULATIONAHA.121.056135
Choi S, Lee S, Seo JW, et al. Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci. Oct 18 2021;36(40):e286. doi:10.3346/jkms.2021.36.e286
Verma AK, Lavine KJ, Lin CY. Myocarditis after Covid-19 mRNA Vaccination. N Engl J Med. Sep 30 2021;385(14):1332-1334. doi:10.1056/NEJMc2109975
Fairweather D, Cooper LT, Jr., Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. Jan 2013;38(1):7-46. doi:10.1016/j.cpcardiol.2012.07.003.
Centers for Disease Control and Prevention. "Summary document for interim clinical considerations for use of COVID-19 vaccines currently authorized or approved in the United States". https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf. Accessed on July,28,2022;
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Don Mathew, Siddharth Agarwal, Akil Sherif, Karandeep Bumrah
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
